MYCN (N-MYC) Gene Amplification by FISH

Casandra

Casandra Test Code AR86514Version 1 (DRAFT)

Performing Lab

Lab ARUP LaboratoriesLab Test ID 3001307CPT Code 88377

MYCN (N-MYC) Gene Amplification by FISH

Also known as: NMYC_FISH

Clinical Use

Order Test

Use

This test is used for prognostic determination in individuals with neuroblastoma or medulloblastoma. It is diagnostic for the MYCN-amplified subgroup of spinal ependymoma. MYCN amplification, with a MYCN/CEP2 ratio of 2.0 or greater, is considered a feature of high-risk disease and an indicator of poor prognosis in neuroblastoma. Amplification is also seen in SHH-activated and group 4 medulloblastomas, with implications for prognosis and therapy response.

Special Instructions

Include surgical pathology report. If multiple specimens (blocks or slides) are sent to ARUP, they must be accompanied by a request for pathologist block/slide selection or individual orders, else they will be held until clarification is provided.

Limitations

This test was developed and its performance characteristics determined by ARUP Laboratories. It has not been cleared or approved by the US Food and Drug Administration. The test is performed in a CLIA certified laboratory and is intended for clinical purposes. Assay range and limit of detection were generated using normal and known positive cases respectively.

Test Details

New York Approved